摘要
目的:观察乙肝病毒(HBV)慢性感染者自体树突状细胞(DC)联合抗病毒治疗的临床效应.方法:采用自身前后对照试验,对41例HBV慢性感染者在试验前均应用IFN-α-2b治疗6 mo,无应答者停药6 mo后继续IFN-α-2b治疗6 mo,同时联合自体DC回输治疗,回输两次为一疗程.疗程结束后1mo检测受试者病毒学、血清学、生化学指标,在回输前后起始的检测指标均一致的基础上观察自身前后的变化.结果:体外培养扩增DC至第6天,HBsAg致敏形成特异性DC疫苗.DC回输后ALT和AST水平较回输前明显降低(t=2.976,P<0.01;t =2.049,P<0.05).HBV DNA应答率为53.7%,DNA拷贝数下降≥210g10.DC回输次数与病毒学应答反应没有相关性(r=0.048,P>0.05),HBV携带时间与病毒学应答反应亦没有相关性(r=0.137,P>0.05).结论:自体DC回输联合IFN-α-2b治疗HBV慢性感染者,生化学和病毒学单项应答反应均优于单纯IFN-α-2b治疗.
AIM： To evaluate the clinical effects of autologous HBsAg-loaded dendritic cells （DCs） combined with anti-viral treatment on patients with chronic hepatitis B virus （HBV） infection.
METHODS： A total of 41 chronic HBV infected subjects were treated with single interferon-α- 2b for 6 months before the trial, and the treatment was stopped for the irresponsive cases. Six months later, the irresponsive cases received the combined therapy of interferon-α-2b and autologous HBsAg-loaded DCs for another 6 months （one course containing twice of re-transfusion）. The changes of virology, serology and biochemistry indexes were observed one month after the end of treatment.
RESULTS： DCs were cultured in vitro. After proliferation for 6 days, DCs were incubated with HBsAg for 1 day to prepare the specific DCs vaccine. The levels of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） were significant decreased after the combined therapy as compared with those before （t = 2.976, P 〈 0.01; t = 2.049, P 〈 0.05）. The response rate of HBV DNA was 53.7%, and the decrease of HBV DNA copies was greater than or equal to 2log10. Neither the injection times of DCs nor the HBV-carrying time had a correlation with the virological responses （r = 0.048, P 〉 0.05; r = 0.137, P 〉 0.05）.
CONCLUSION： Combined treatment of autologous DCs vaccine and interferon-α-2b has a favorable effect on patients with chronic HBV infection.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第11期1232-1236,共5页
World Chinese Journal of Digestology
基金
河北省科技厅资助项目
No.04276101D-40~~
